期刊
VACCINES
卷 9, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9020085
关键词
cancer vaccines; cancer antigens; tumor-specific antigens; tumor-associated antigens; neoantigens; cancer-germline antigens
资金
- Chinese Scholarship Council [201906310088]
- Ministry of Education and Science of the Russian Federation
Cancer vaccines utilize the host's immune system specificity to eliminate tumor cells, with antigen selection and application playing a critical role in efficacy. Tumor-associated antigens and tumor-specific antigens have different characteristics and applications in vaccine development.
Unlike traditional cancer therapies, cancer vaccines (CVs) harness a high specificity of the host's immunity to kill tumor cells. CVs can train and bolster the patient's immune system to recognize and eliminate malignant cells by enhancing immune cells' identification of antigens expressed on cancer cells. Various features of antigens like immunogenicity and avidity influence the efficacy of CVs. Therefore, the choice and application of antigens play a critical role in establishing and developing CVs. Tumor-associated antigens (TAAs), a group of proteins expressed at elevated levels in tumor cells but lower levels in healthy normal cells, have been well-studied and developed in CVs. However, immunological tolerance, HLA restriction, and adverse events are major obstacles that threaten TAA-based CVs' efficacy due to the self-protein characteristic of TAAs. As abnormal proteins that are completely absent from normal cells, tumor-specific antigens (TSAs) can trigger a robust immune response against tumor cells with high specificity and without going through central tolerance, contributing to cancer vaccine development feasibility. In this review, we focus on the unique features of TAAs and TSAs and their application in vaccines, summarizing their performance in preclinical and clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据